Endoscopic features and clinical importance of autoimmune gastritis. Issue 4 (10th November 2021)

• Record Type: Journal Article
• Authors: Kamada, Tomoari; Maruyama, Yasuhiko; Monobe, Yasumasa; Haruma, Ken
• Is Part Of: Digestive endoscopy. Volume 34:Issue 4(2022)
• Page Start: 700
• Page End: 713
• Publication Date: 2021-11-10
• Subjects: autoimmune gastritis -- autoimmune polyendocrine syndrome -- corpus‐predominant atrophy -- gastric cancer -- gastric neuroendocrine tumor; Digestive organs -- Diseases -- Periodicals; Digestive organs -- Diseases -- Diagnosis -- Periodicals; Endoscopy -- Periodicals; Digestive System Diseases -- diagnosis -- Periodicals; Digestive System Diseases -- therapy -- Periodicals; Endoscopy -- Periodicals; 616.3
• DOI: 10.1111/den.14175
• Languages: English
• ISSNs: 0915-5635

Abstract

Abstract : Autoimmune gastritis (AIG) is a special type of chronic gastritis characterized by autoimmune disorders caused by cellular immunity, resulting in the destruction of parietal cells and production of antiparietal cell antibodies. Endoscopic findings of AIG are mainly characterized by corpus‐dominant advanced atrophy. The antral area is generally considered to have no or mild atrophy; however, there are cases wherein the gastric mucosa is red or faded due to past infection with Helicobacter pylori or bile reflux. Currently, there are no diagnostic criteria for AIG in Japan, and it is important to make a diagnosis based on the presence of gastric autoantibodies and characteristic endoscopic and histological findings. AIG is associated with gastric cancer, neuroendocrine tumors (NETs), and other autoimmune diseases, such as thyroid diseases, anemia, and neurological symptoms due to impaired absorption of iron and vitamin B12, and thus requires systemic treatment. The significance of diagnosing AIG is to include patients as a high‐risk group for the development of gastric cancer and gastric NETs, provide an opportunity to detect autoimmune endocrine diseases, and initiate therapeutic intervention before anemia and neurological symptoms develop. It is important to pay close attention to the occurrence of AIG comorbidities not only at the time of AIG diagnosis but also during follow‐up after detection.